February 24 2016, 15.52 PM IST || Pocket News Alert
New Delhi, February 24, 2016: Dabur India Ltd has inked a license agreement with the Government of India to commercially produce two new Ayurvedic drugs – Ayush-64 treatment of Malaria and Ayush-82 for management of Diabetes. Dabur India Ltd also signed a Memorandum of Understanding (MoU) with the Central Council of Research in Ayurvedic Sciences (CCRAS), an apex research body under the Ministry of AYUSH, Government of India, for collaboration and co-operation in pharmaceutical R&D for different novel dosage forms and drug development in Ayurveda.
Dabur India Ltd said it is preparing to commercially produce the two new Ayurvedic medicines within the next 6 months and these medicines will be available in various formats. The Ayurvedic formulations for both these medicines were developed by CCRAS. The Licence agreements were signed by Dr. H. Purushotham on behalf of National Research Development Corporation (NRDC) and Dr. J. L. N. Sastry, Head-Healthcare Research, Dabur India Ltd.
The Ayurvedic drug Ayush-64 is highly effective for the treatment of Malaria. In view of its wide prevalence and drug resistant malarial parasite, a poly-herbal non-toxicdrug has been developed by CCRAS after carrying out extensive pharmacological, toxicological and Clinical studies. Ayush-82, an anti diabetic drug also developed by CCRAS is a combination of known and tested hypoglycemic drugs. Its clinical studies have been done extensively. The use of these two drugs would help millions of people suffering from Malaria and Diabetes, CCRAS said.
Since 1976, CCRAS has developed many important therapeutic agents but lack of commercial promotion and developmental activities kept this research in dormitory. CCRAS is now aggressively pursuing their tie-up with good and capable industry partners to make these Ayurvedic medicines commercially available.
Speaking on the occasion, Dr J. L. N. Sastry said Dabur has been emphasizing the necessity to bring out the findings of the apex research council of Ayurveda and present it to the public for their benefit. "We have now signed a comprehensive MoU with CCRAS to co-operate with each other in the field of Ayurvedic Research and Development," he added. CCRAS and Dabur will explore the feasibility and possibility of collaboration in diverse areas of R&D relating to Ayurvedic medicines. This collaboration will pave a new horizon in Ayurvedic drug development, utilizing optimally the existing resources of CCRAS and Dabur R&D, on public private partnership model. The collaboration will be at various stages of drug development like formulation development, analytical development, pre-clinical studies, clinical studies etc. "After successful completion of the project on a specific product, Dabur will market the same with its strong distribution network in India. Dabur may also market some of the already developed products by CCRAS," Dr Sastry said.
This is a new milestone in the history of Ayurveda where CCRAS, the apex body in the field of Research in Ayurveda, and Dabur India Ltd, the world's largest Ayurvedic products maker, have come together for the development of Ayurveda.
